[Form 4] BioXcel Therapeutics, Inc. Insider Trading Activity
BioXcel Therapeutics, Inc. (BTAI) 鈥� Form 4 (filed 08/05/2025)
Chief Financial Officer Richard I. Steinhart reported the grant of 9,000 Restricted Stock Units (RSUs) on 08/01/2025. Each RSU entitles the holder to one share of BioXcel common stock at no cost. The award vests 100% within 30 days of nine months after the grant date, provided Steinhart remains employed by the company or a subsidiary on the vesting date. Following the transaction, he beneficially owns 9,000 derivative securities; no direct common-stock holdings, dispositions or sales were disclosed. The filing records a routine, service-based equity incentive and does not reference any 10b5-1 trading plan.
BioXcel Therapeutics, Inc. (BTAI) 鈥� Modulo 4 (depositato il 05/08/2025)
Il Chief Financial Officer Richard I. Steinhart ha riportato la concessione di 9.000 Unit脿 Azionarie Vincolate (RSU) il 01/08/2025. Ogni RSU d脿 diritto al titolare a una azione ordinaria di BioXcel senza alcun costo. Il premio matura al 100% entro 30 giorni dopo nove mesi dalla data di assegnazione, a condizione che Steinhart rimanga impiegato presso la societ脿 o una sua controllata alla data di maturazione. Dopo la transazione, detiene beneficiariamente 9.000 titoli derivati; non sono state dichiarate partecipazioni dirette in azioni ordinarie, n茅 cessioni o vendite. Il deposito registra un incentivo azionario ordinario basato sul servizio e non fa riferimento a nessun piano di trading 10b5-1.
BioXcel Therapeutics, Inc. (BTAI) 鈥� Formulario 4 (presentado el 05/08/2025)
El Director Financiero Richard I. Steinhart inform贸 la concesi贸n de 9,000 Unidades de Acciones Restringidas (RSU) el 01/08/2025. Cada RSU otorga al titular una acci贸n com煤n de BioXcel sin costo alguno. La concesi贸n se consolida al 100% dentro de los 30 d铆as posteriores a nueve meses desde la fecha de otorgamiento, siempre que Steinhart siga empleado por la empresa o una subsidiaria en la fecha de consolidaci贸n. Tras la transacci贸n, posee beneficiosamente 9,000 valores derivados; no se revelaron tenencias directas de acciones comunes, ni disposiciones o ventas. La presentaci贸n registra un incentivo de capital basado en el servicio rutinario y no menciona ning煤n plan de negociaci贸n 10b5-1.
BioXcel Therapeutics, Inc. (BTAI) 鈥� 鞏戩嫕 4 (2025雲� 8鞗� 5鞚� 鞝滌稖)
斓滉碃鞛毂呾瀯鞛� 毽矘霌� I. 鞀ろ儉鞚疙晿韸鸽姅 2025雲� 8鞗� 1鞚检棎 9,000臧滌潣 鞝滍暅欤检嫕雼渼(RSU) 攵�鞐�毳� 氤搓碃頄堨姷雼堧嫟. 臧� RSU電� 氤挫湢鞛愳棎瓴� 牍勳毄 鞐嗢澊 BioXcel 氤错喌欤� 1欤茧ゼ 氚涭潉 甓岆Μ毳� 攵�鞐暕雼堧嫟. 鞚� 氤挫儊鞚� 攵�鞐澕搿滊秬韯� 9臧滌洈 頉� 30鞚� 鞚措偞鞐� 100% 氩犾姢韺�霅橂┌, 鞀ろ儉鞚疙晿韸戈皜 氩犾姢韺呾澕鞐� 須岇偓 霕愲姅 鞛愴殞靷棎 瓿犾毄霅橃柎 鞛堨柎鞎� 頃╇媹雼�. 瓯半灅 頉� 攴鸽姅 9,000臧滌潣 韺岇儩歃濌秾鞚� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 歆侅爲 氤错喌欤� 氤挫湢, 觳橂秳 霕愲姅 韺愲Г電� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�. 鞚� 鞝滌稖靹滊姅 鞚茧皹鞝侅澑 靹滊箘鞀� 旮半皹 欤检嫕 鞚胳劶韹半笇毳� 旮半頃橂┌ 10b5-1 瓯半灅 瓿勴殟鞐� 雽�頃挫劀電� 鞏戈笁頃橃 鞎婌姷雼堧嫟.
BioXcel Therapeutics, Inc. (BTAI) 鈥� Formulaire 4 (d茅pos茅 le 05/08/2025)
Le Directeur Financier Richard I. Steinhart a d茅clar茅 l'octroi de 9 000 unit茅s d鈥檃ctions restreintes (RSU) le 01/08/2025. Chaque RSU donne droit 脿 son d茅tenteur 脿 une action ordinaire de BioXcel sans frais. La r茅compense devient pleinement acquise 脿 100 % dans les 30 jours suivant neuf mois apr猫s la date d鈥檕ctroi, 脿 condition que Steinhart soit toujours employ茅 par la soci茅t茅 ou une filiale 脿 la date d鈥檃cquisition. Suite 脿 la transaction, il d茅tient de mani猫re b茅n茅ficiaire 9 000 titres d茅riv茅s ; aucune d茅tention directe d鈥檃ctions ordinaires, cession ou vente n鈥檃 茅t茅 divulgu茅e. Le d茅p么t enregistre une incitation en actions bas茅e sur le service habituel et ne fait pas r茅f茅rence 脿 un plan de n茅gociation 10b5-1.
BioXcel Therapeutics, Inc. (BTAI) 鈥� Formular 4 (eingereicht am 05.08.2025)
Chief Financial Officer Richard I. Steinhart meldete die Gew盲hrung von 9.000 Restricted Stock Units (RSUs) am 01.08.2025. Jede RSU berechtigt den Inhaber zum kostenlosen Erwerb einer BioXcel-Stammaktie. Die Zuteilung f盲llt zu 100 % innerhalb von 30 Tagen nach neun Monaten ab dem Gew盲hrungsdatum an, vorausgesetzt, Steinhart ist am Vesting-Datum weiterhin bei der Gesellschaft oder einer Tochtergesellschaft besch盲ftigt. Nach der Transaktion besitzt er wirtschaftlich 9.000 derivative Wertpapiere; keine direkten Stammaktienbest盲nde, Ver盲u脽erungen oder Verk盲ufe wurden offengelegt. Die Meldung dokumentiert eine routinem盲脽ige, dienstleistungsbasierte Aktienverg眉tung und verweist nicht auf einen 10b5-1 Handelsplan.
- Alignment of interests: 9,000 RSUs link CFO compensation to share performance, encouraging value creation.
- Minor dilution: New equity issuance, though immaterial relative to total shares, marginally increases share count.
Insights
TL;DR: Routine RSU grant, modest alignment; immaterial to valuation.
The 9,000-unit RSU award is standard for executive compensation and represents a small fraction of BTAI鈥檚 ~29 million outstanding shares, thus creating negligible dilution. The single-line filing shows no share sales, so insider sentiment cannot be inferred beyond continued employment commitment. Investors may view the award as modestly positive because it aligns the CFO鈥檚 incentives with shareholders, but the event is not financially material and carries no immediate earnings or cash-flow impact.
TL;DR: Standard incentive; signals retention focus, low impact.
The RSU grant vests in roughly nine months, a shorter horizon than typical three-to-four-year vesting schedules, indicating a near-term retention mechanism for the recently appointed CFO. No 10b5-1 plan accompanies the grant, suggesting flexibility in future selling decisions once shares are delivered. Governance risk is minimal; disclosure is timely and complete. Overall impact on shareholder rights and dilution is de minimis.
BioXcel Therapeutics, Inc. (BTAI) 鈥� Modulo 4 (depositato il 05/08/2025)
Il Chief Financial Officer Richard I. Steinhart ha riportato la concessione di 9.000 Unit脿 Azionarie Vincolate (RSU) il 01/08/2025. Ogni RSU d脿 diritto al titolare a una azione ordinaria di BioXcel senza alcun costo. Il premio matura al 100% entro 30 giorni dopo nove mesi dalla data di assegnazione, a condizione che Steinhart rimanga impiegato presso la societ脿 o una sua controllata alla data di maturazione. Dopo la transazione, detiene beneficiariamente 9.000 titoli derivati; non sono state dichiarate partecipazioni dirette in azioni ordinarie, n茅 cessioni o vendite. Il deposito registra un incentivo azionario ordinario basato sul servizio e non fa riferimento a nessun piano di trading 10b5-1.
BioXcel Therapeutics, Inc. (BTAI) 鈥� Formulario 4 (presentado el 05/08/2025)
El Director Financiero Richard I. Steinhart inform贸 la concesi贸n de 9,000 Unidades de Acciones Restringidas (RSU) el 01/08/2025. Cada RSU otorga al titular una acci贸n com煤n de BioXcel sin costo alguno. La concesi贸n se consolida al 100% dentro de los 30 d铆as posteriores a nueve meses desde la fecha de otorgamiento, siempre que Steinhart siga empleado por la empresa o una subsidiaria en la fecha de consolidaci贸n. Tras la transacci贸n, posee beneficiosamente 9,000 valores derivados; no se revelaron tenencias directas de acciones comunes, ni disposiciones o ventas. La presentaci贸n registra un incentivo de capital basado en el servicio rutinario y no menciona ning煤n plan de negociaci贸n 10b5-1.
BioXcel Therapeutics, Inc. (BTAI) 鈥� 鞏戩嫕 4 (2025雲� 8鞗� 5鞚� 鞝滌稖)
斓滉碃鞛毂呾瀯鞛� 毽矘霌� I. 鞀ろ儉鞚疙晿韸鸽姅 2025雲� 8鞗� 1鞚检棎 9,000臧滌潣 鞝滍暅欤检嫕雼渼(RSU) 攵�鞐�毳� 氤搓碃頄堨姷雼堧嫟. 臧� RSU電� 氤挫湢鞛愳棎瓴� 牍勳毄 鞐嗢澊 BioXcel 氤错喌欤� 1欤茧ゼ 氚涭潉 甓岆Μ毳� 攵�鞐暕雼堧嫟. 鞚� 氤挫儊鞚� 攵�鞐澕搿滊秬韯� 9臧滌洈 頉� 30鞚� 鞚措偞鞐� 100% 氩犾姢韺�霅橂┌, 鞀ろ儉鞚疙晿韸戈皜 氩犾姢韺呾澕鞐� 須岇偓 霕愲姅 鞛愴殞靷棎 瓿犾毄霅橃柎 鞛堨柎鞎� 頃╇媹雼�. 瓯半灅 頉� 攴鸽姅 9,000臧滌潣 韺岇儩歃濌秾鞚� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 歆侅爲 氤错喌欤� 氤挫湢, 觳橂秳 霕愲姅 韺愲Г電� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�. 鞚� 鞝滌稖靹滊姅 鞚茧皹鞝侅澑 靹滊箘鞀� 旮半皹 欤检嫕 鞚胳劶韹半笇毳� 旮半頃橂┌ 10b5-1 瓯半灅 瓿勴殟鞐� 雽�頃挫劀電� 鞏戈笁頃橃 鞎婌姷雼堧嫟.
BioXcel Therapeutics, Inc. (BTAI) 鈥� Formulaire 4 (d茅pos茅 le 05/08/2025)
Le Directeur Financier Richard I. Steinhart a d茅clar茅 l'octroi de 9 000 unit茅s d鈥檃ctions restreintes (RSU) le 01/08/2025. Chaque RSU donne droit 脿 son d茅tenteur 脿 une action ordinaire de BioXcel sans frais. La r茅compense devient pleinement acquise 脿 100 % dans les 30 jours suivant neuf mois apr猫s la date d鈥檕ctroi, 脿 condition que Steinhart soit toujours employ茅 par la soci茅t茅 ou une filiale 脿 la date d鈥檃cquisition. Suite 脿 la transaction, il d茅tient de mani猫re b茅n茅ficiaire 9 000 titres d茅riv茅s ; aucune d茅tention directe d鈥檃ctions ordinaires, cession ou vente n鈥檃 茅t茅 divulgu茅e. Le d茅p么t enregistre une incitation en actions bas茅e sur le service habituel et ne fait pas r茅f茅rence 脿 un plan de n茅gociation 10b5-1.
BioXcel Therapeutics, Inc. (BTAI) 鈥� Formular 4 (eingereicht am 05.08.2025)
Chief Financial Officer Richard I. Steinhart meldete die Gew盲hrung von 9.000 Restricted Stock Units (RSUs) am 01.08.2025. Jede RSU berechtigt den Inhaber zum kostenlosen Erwerb einer BioXcel-Stammaktie. Die Zuteilung f盲llt zu 100 % innerhalb von 30 Tagen nach neun Monaten ab dem Gew盲hrungsdatum an, vorausgesetzt, Steinhart ist am Vesting-Datum weiterhin bei der Gesellschaft oder einer Tochtergesellschaft besch盲ftigt. Nach der Transaktion besitzt er wirtschaftlich 9.000 derivative Wertpapiere; keine direkten Stammaktienbest盲nde, Ver盲u脽erungen oder Verk盲ufe wurden offengelegt. Die Meldung dokumentiert eine routinem盲脽ige, dienstleistungsbasierte Aktienverg眉tung und verweist nicht auf einen 10b5-1 Handelsplan.
FAQ
What insider transaction did BTAI report on August 5, 2025?
When will the 9,000 RSUs granted to BTAI's CFO vest?
Did the Form 4 show any stock sales by the CFO?
What is the exercise price of the RSUs granted to the CFO of BTAI?
How many derivative securities does CFO Richard Steinhart own after this grant?
